Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ruderman

Showing results (11-20 of 79) with videos related to

Pageof 8
Sort By:
Expert Opinion on Investigational Drugs|December 17, 2009
Novel TNF antagonists for the treatment of rheumatoid arthritisLaisvyde Statkute, Eric M Ruderman
Bulletin of the NYU Hospital for Joint Diseases|October 26, 2010
Anti-interleukin-6 therapy in rheumatoid arthritisRobert Woodrick, Eric M Ruderman
Mayo Clinic Proceedings|November 21, 2021
A Road Map of the Axial Spondyloarthritis ContinuumSergio Schwartzman, Eric M Ruderman
Rheumatic Diseases Clinics of North America|July 18, 2025
Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease: Current StateEric M Ruderman, Kenneth B Gordon
Arthritis Research & Therapy|September 1, 2011
More than just B-cell inhibitionEric M Ruderman, Richard M Pope
Bulletin of the NYU Hospital for Joint Diseases|November 1, 2011
Interleukin 6 inhibition - RA and beyondRobert S Woodrick, Eric M Ruderman
Postgraduate Medicine|December 8, 2004
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destructionSakeba N Issa, Eric M Ruderman
Bulletin of the NYU Hospital for Joint Diseases|December 25, 2012
IL-6 inhibition for the treatment of rheumatoid arthritis and other conditionsRobert S Woodrick, Eric M Ruderman
Ophthalmic Surgery|May 1, 1989
Low-dose 5-fluorouracil and glaucoma filtration surgeryJ H Rabowsky, J M Ruderman
Arthritis Research & Therapy|April 19, 2005
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritisEric M Ruderman, Richard M Pope
Pageof 8

Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|December 17, 2009
Novel TNF antagonists for the treatment of rheumatoid arthritisLaisvyde Statkute, Eric M Ruderman
Bulletin of the NYU Hospital for Joint Diseases|October 26, 2010
Anti-interleukin-6 therapy in rheumatoid arthritisRobert Woodrick, Eric M Ruderman
Mayo Clinic Proceedings|November 21, 2021
A Road Map of the Axial Spondyloarthritis ContinuumSergio Schwartzman, Eric M Ruderman
Rheumatic Diseases Clinics of North America|July 18, 2025
Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease: Current StateEric M Ruderman, Kenneth B Gordon
Arthritis Research & Therapy|September 1, 2011
More than just B-cell inhibitionEric M Ruderman, Richard M Pope
Bulletin of the NYU Hospital for Joint Diseases|November 1, 2011
Interleukin 6 inhibition - RA and beyondRobert S Woodrick, Eric M Ruderman
Postgraduate Medicine|December 8, 2004
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destructionSakeba N Issa, Eric M Ruderman
Bulletin of the NYU Hospital for Joint Diseases|December 25, 2012
IL-6 inhibition for the treatment of rheumatoid arthritis and other conditionsRobert S Woodrick, Eric M Ruderman
Ophthalmic Surgery|May 1, 1989
Low-dose 5-fluorouracil and glaucoma filtration surgeryJ H Rabowsky, J M Ruderman
Arthritis Research & Therapy|April 19, 2005
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritisEric M Ruderman, Richard M Pope
Pageof 8